Wegovy (Semaglutide) Weight Loss Injection (1mg)

Wegovy (Semaglutide) Weight Loss Injection (1mg)

Clinically Proven GLP‑1 Therapy for Sustainable Weight Reduction & Appetite Control

Wegovy (Semaglutide) 1 mg is a prescription‑strength GLP‑1 receptor agonist designed to support medically supervised weight loss in adults with obesity or overweight accompanied by weight‑related health conditions. By mimicking the natural hormone GLP‑1, Wegovy regulates appetite, slows gastric emptying, and improves metabolic function — resulting in reduced hunger, smaller portion sizes, and consistent fat loss.

The 1 mg dose is part of the step‑up titration schedule, helping patients adjust gradually while minimizing gastrointestinal side effects.

Key Features

• Contains Semaglutide, a clinically proven GLP‑1 analogue
• Reduces appetite and cravings
• Slows gastric emptying for prolonged satiety
• Supports steady, sustainable weight loss
• Improves metabolic markers (glucose, insulin sensitivity)
• Once‑weekly, pre‑filled injection pen
• Part of the official Wegovy titration protocol

How Wegovy Works

Wegovy activates GLP‑1 receptors, leading to:

• Reduced hunger signals
• Lower caloric intake
• Improved blood sugar control
• Enhanced fat metabolism
• Decreased food reward response

This mechanism supports long‑term weight management when combined with lifestyle changes.

Indications

Wegovy 1 mg is prescribed for:

• Adults with BMI ≥30
• Adults with BMI ≥27 plus a weight‑related condition (e.g., hypertension, prediabetes, dyslipidemia)
• Patients requiring medical weight management under professional supervision

Benefits

• Significant weight reduction over 6–12 months
• Reduced waist circumference
• Improved energy and metabolic health
• Lower risk of obesity‑related complications
• Convenient weekly dosing

Dosage & Titration

The 1 mg pen is the fourth step in the Wegovy dose escalation schedule:

WeekDose1–40.25 mg5–80.5 mg9–121 mg13–161.7 mg17+2.4 mg (maintenance)

The gradual increase helps reduce nausea and improve tolerability.

Safety Information

Common side effects:

• Nausea
• Bloating
• Fatigue
• Mild gastrointestinal discomfort

Not suitable for:

• Pregnant or breastfeeding individuals
• Patients with personal/family history of medullary thyroid carcinoma
• Individuals with MEN2 syndrome

Wegovy must be used under medical supervision.

Professional Use & Prescription Requirement

Wegovy (Semaglutide) is a prescription‑only medication and must be provided by a licensed healthcare professional.
It is not a cosmetic product and requires medical evaluation before use